Cargando…

Efficacy of gefapixant, a P2X(3) antagonist, for lung cancer-related cough: a case report

Cough is a frequent symptom accompanied by lung cancer. More potent antitussive treatment for this complex and distressing symptom is required, but anti-cancer chemotherapy cannot fully manage the cough. Inhibition of vagal nerves might control coughing in patients with troublesome lung cancer-relat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishiura, Yoshihisa, Nomura, Shosaku, Ishii, Yuka, Imai, Kai, Sawai, Yusuke, Tamaki, Takeshi, Shimizu, Toshiki, Miyashita, Naoyuki, Ito, Tomoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467400/ https://www.ncbi.nlm.nih.gov/pubmed/37641866 http://dx.doi.org/10.1177/03000605231194890

Ejemplares similares

Efficacy of Gefapixant, a P2X(3) Antagonist, for Refractory Atopic Cough
por: Ishiura, Yoshihisa, et al.
Publicado: (2023)

Tiotropium Add-On and Treatable Traits in Asthma-COPD Overlap: A Real-World Pilot Study
por: Ishiura, Yoshihisa, et al.
Publicado: (2022)

Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap
por: Ishiura, Yoshihisa, et al.
Publicado: (2020)

A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis
por: Ishii, Nobuyasu, et al.
Publicado: (2021)

Association of High Mobility Group Box-Protein 1 and Platelet Microparticles in Patients After Hematopoietic Stem Cell Transplantation
por: Nomura, Shosaku, et al.
Publicado: (2023)

Clinical Formulation Bridging of Gefapixant, a P2X3‐Receptor Antagonist, for the Treatment of Chronic Cough
por: Gupta, Pranav, et al.
Publicado: (2022)

Effect of triple therapy in patients with asthma-COPD overlap
por: Ishiura, Yoshihisa, et al.
Publicado: (2019)

Localized lymphadenopathy with myelodysplastic syndrome associated with tuberculosis
por: Nakaya, Aya, et al.
Publicado: (2019)

Population pharmacokinetic analysis of the P2X3‐receptor antagonist gefapixant
por: Chawla, Akshita, et al.
Publicado: (2023)

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
por: Muccino, David R., et al.
Publicado: (2020)

Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
por: Morice, Alyn H., et al.
Publicado: (2021)

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks
por: Birring, Surinder S., et al.
Publicado: (2023)

P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough
por: Cui, Wen-Wen, et al.
Publicado: (2022)

Early identification of novel coronavirus (COVID-19) pneumonia using clinical and radiographic findings
por: Miyashita, Naoyuki, et al.
Publicado: (2022)

A warning related to predicting the severity of COVID-19 pneumonia using the A-DROP scoring system
por: Miyashita, Naoyuki, et al.
Publicado: (2022)

Clinical Differences between Community-Acquired Mycoplasma pneumoniae Pneumonia and COVID-19 Pneumonia
por: Miyashita, Naoyuki, et al.
Publicado: (2022)

Clinical features of nursing and healthcare-associated pneumonia due to COVID-19
por: Miyashita, Naoyuki, et al.
Publicado: (2022)

Changes in diagnostic usefulness of the JRS scoring system in COVID-19 pneumonia by SARS-CoV-2 vaccination
por: Miyashita, Naoyuki, et al.
Publicado: (2022)

Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials
por: Chuang, Min-Hsiang, et al.
Publicado: (2023)

Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial
por: Martinez, Fernando J., et al.
Publicado: (2021)

The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2023)

Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial
por: Smith, Jaclyn A., et al.
Publicado: (2022)

Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports
por: Ito, Tomoki, et al.
Publicado: (2014)

Primary intrahepatic malignant mesothelioma with multiple lymphadenopathies due to non-tuberculous mycobacteria: A case report and review of the literature
por: INAGAKI, NORIKO, et al.
Publicado: (2013)

Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
por: Smith, Jaclyn A., et al.
Publicado: (2022)

Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients
por: Nomura, Shosaku, et al.
Publicado: (2012)

Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
por: Miyashita, Naoyuki, et al.
Publicado: (2023)

Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy
por: KIBATA, KAYOKO, et al.
Publicado: (2013)

Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer
por: SHIMIZU, TOSHIKI, et al.
Publicado: (2013)

Safety and efficacy of gefapixant, a novel drug for the treatment of chronic cough: A systematic review and meta-analysis of randomized controlled trials
por: Abu-Zaid, Ahmed, et al.
Publicado: (2021)

Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans
por: Nussbaum, Jesse C., et al.
Publicado: (2022)

Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β(1), and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia
por: Nomura, Shosaku, et al.
Publicado: (2018)

Platelet-Derived Microparticles are an Important Biomarker in Patients with Cancer-Associated Thrombosis
por: Yamanaka, Yuta, et al.
Publicado: (2019)

Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients
por: Sawai, Yusuke, et al.
Publicado: (2020)

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin
por: McCrea, Jacqueline B., et al.
Publicado: (2021)

Microparticles as Biomarkers of Blood Coagulation in Cancer
por: Nomura, Shosaku, et al.
Publicado: (2015)

Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation
por: Ozasa, Ryotaro, et al.
Publicado: (2012)

Phosphodiesterase 3 inhibition and cough in elderly asthmatics
por: Ishiura, Yoshihisa, et al.
Publicado: (2005)

Role of COX-2 in cough reflex sensitivity to inhaled capsaicin in patients with sinobronchial syndrome
por: Ishiura, Yoshihisa, et al.
Publicado: (2010)

Extracellular Vesicle-Related Thrombosis in Viral Infection
por: Nomura, Shosaku, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j0762talg2t1vt37fpf4k8elfg